December 13, 2018

Modulight and Bausch + Lomb team for ocular laser

The laser will be used to treat choroidal neovascularization in the eye.
The laser will be used to treat choroidal neovascularization in the eye.
Shutterstock

Finnish medical laser technology developer Modulight has entered into an exclusive agreement with global eye health company Bausch + Lomb to develop a new photodynamic laser.

The two companies will collaborate and develop a new laser to be used specifically with Bausch + Lomb’s VISUDYNE photodynamic therapy (PDT).

The method uses the injectable photosensitising drug VISUDYNE, which is activated through the use of a photodynamic laser, to treat choroidal neovascularisation in the eye. It helps to prevent further disease progression and helps patients to maintain their vision by destroying abnormal choroidal blood vessels.

“Modulight works closely with healthcare companies to customise its broad portfolio of laser technology solutions to specifically address their needs,” said Seppo Orsila, executive chairperson at Modulight.

“Bausch + Lomb has identified a significant need in the ophthalmic industry and we believe this is a great opportunity to develop a state-of-the-art photodynamic laser to allow customers to continue to provide this type of therapy for their patients. We look forward to a strong promising collaboration.”

Share: